This Thursday, July 19, 2018, the NYU Center for Bioethics Director Matthew Liao will be presenting the keynote at the North American Society for Social Philosophy Conference. Two of the Center’s MA candidates, Michael Corbett and John James, will also be presenting papers. For more information, see the North American Society for Social Philosophy website: http://www.northamericansocietyforsocialphilosophy.org/program/.
Classical models of antisocial behavior propose that violence arises out of a failure of lateral prefrontal cortex (LPFC) to “put the brakes” on aggressive impulses originating in subcortical regions such as the amygdala and striatum. A new, alternative model proposes that LPFC does not directly inhibit aggressive impulses, but instead flexibly modulates the value of aggressive acts via corticostriatal circuits. This mechanism implies that the moral value of actions is flexibly guided by neural representations of social norms. If norms change, so then do the values that guide actions. Supporting this view, re-framing decisions to harm others as being in service of a noble cause eliminated moral preferences. Implications for models of moral responsibility will be discussed.
Dr. Molly Crockett is an Assistant Professor of Psychology at Yale University and a Distinguished Research Fellow at the Oxford Centre for Neuroethics. Prior to joining Yale, Dr Crockett was a faculty member at the University of Oxford’s Department of Experimental Psychology and a Fellow of Jesus College. She holds a BSc in Neuroscience from UCLA and a PhD in Experimental Psychology from the University of Cambridge, and completed a Wellcome Trust Postdoctoral Fellowship with economists and neuroscientists at the University of Zürich and University College London. For more, visit here.
4:00 PM-6:00 PM
5 Washington Place, Room 202 New York, NY 10003
Reception to follow
Dr. Bruce Albala has been working to find a treatment for Alzheimer’s disease (AD) and the related dementias for over 30 years and is currently leading a global AD clinical trial. He has served as a clinical investigator, researcher and in various roles in and supporting the pharmaceutical industry during this time.
The talk will cover practical and theoretical issues on the diagnosis of AD, identifying the proper population, designing the clinical studies and implementing them on a truly global level while identifying the health, legal, business and ethical challenges.
Dr. Bruce J. Albala has extensive experience in both basic and clinical medical research. After receiving his Ph.D. in Biopsychology from Syracuse University (Syracuse, NY) in 1979 he went to Albert Einstein College of Medicine (Bronx, NY) where he was first a research fellow in the departments of Psychiatry and Neurology and later a Clinical Instructor in the Department of Neurology. After a brief period as a visiting scientist at the National Institutes of Mental Health (Bethesda, MD) he joined the clinical research group at Ayerst Laboratories, a division of American Home Products Corporation (New York, NY) in the beginning of 1984. In 1986, Dr. Albala went on to become a principle of American BioInterface Corporation (New York, NY) serving as Vice President of Scientific Affairs and a Director of this innovative bioresearch and medical device company. Dr. Albala joined Clinical Technologies Associates (CTA), Inc. (Elmsford, NY), now Emisphere Technology in 1989 as Vice President and Director of Clinical Research. He was elected to the board of Directors of this publicly held company and served as corporate Secretary. Dr. Albala was responsible for both CTA’s specialty Contract Research Organization (CRO) activities as well as its in-patient and outpatient clinical units. In 1991 Dr. Albala became the president and CEO of CTA Bio Services, Inc. (Elmsford, NY) a CRO company that also conducted both in-patient phase I studies and outpatient clinical trials for the pharmaceutical industry. Dr. Albala served as a clinical Investigator in over two dozen pharmaceutical trials. In 1996 Dr. Albala joined Medeva, now a part of UCB. Initially overseeing vaccine development in the U.S. Dr. Albala then became Senior Director of Clinical Operations for Medeva Development’s (MD) North American division and was promoted to Vice President, Clinical Operations for all of MDs world-wide units. Dr. Albala continued to provide clinical and regulatory consulting services to the pharmaceutical and medical device community as president and lead consultant in CNS Bio Services, Inc.
Dr. Albala joined Shionogi USA, Inc. in April 2002. Shionogi – one of the oldest pharmaceutical companies in Japan – was in a joint venture (JV) with GlaxoSmithKline, Inc. Dr. Albala as the Vice President of Clinical Development and Head of the CNS Program set strategy and oversaw all CNS activity for both Shionogi and as the lead CNS representative to the Shionogi-GlaxoSmithKline Pharmaceuticals JV. The global programs that Dr Albala was responsible for included Alzheimer’s disease (AD), ataxias, ischemic and hemorrhagic stroke, Parkinson’s disease and a large program in obesity and another in analgesia complications. Dr. Albala joined the Neuroscience Product Creation Unit (PCU) of another major Japanese pharmaceutical company Eisai Inc. as an Executive Director of Clinical Development in 2010. His major focus at Eisai is AD and he is the International Project Team Leader (IPTL) for one of the global programs exploring disease modification therapies. As IPTL he guides both the internal and external pre-clinical work in these areas as well as being directly responsible for all clinical activities on a global level and representing the group at AD and neuroscience meetings.
Dr. Albala has made numerous presentations at scientific meetings and has scientific publications in both the basic and clinical sciences and has taught courses in the biological, psychological, pharmacological and neurosciences at Syracuse University, Hunter College (City University of New York) and Cooper Union and has lectured on many industry topics. Dr. Albala has U.S. patents for both medical devices as well as instruments used in clinical research settings.
Friday, December 1, 2017
4:00 PM – 6:00 PM
5 Washington Place, Room 302
Reception to follow
There has been a recent flourishing of scientific and philosophical work on consciousness in non-human animals. This conference will bring together philosophers and scientists to ask questions such as: Are invertebrates conscious? Do fish feel pain? Are non-human mammals self-conscious? How did consciousness evolve? How does research on animal consciousness affect the ethical treatment of animals? What is the impact of animal consciousness upon theories of consciousness and vice versa? What are the best methods for assessing consciousness in non-human animals?
Speakers and panelists include:
Colin Allen (University of Pittsburgh, Department of History & Philosophy of Science), Andrew Barron (Macquarie, Cognitive Neuroethology), Victoria Braithwaite (Penn State, Biology), Peter Carruthers (Maryland, Philosophy), Marian Dawkins(Oxford, Zoology), Daniel Dennett (Tufts, Philosophy), Stuart Derbyshire (National University of Singapore, Neuroscience), David Edelman (San Diego, Neuroscience), Todd Feinberg (Mt. Sinai, Neurology), Peter Godfrey-Smith (Sydney, Philosophy), Lori Gruen (Wesleyan, Philosophy), Brian Hare (Duke, Evolutionary Anthropology), Stevan Harnad (Montreal, Cognitive Science), Alexandra Horowitz (Barnard, Psychology), Eva Jablonka (Tel Aviv, Cohn Institute), Jennifer Jacquet (NYU, Environmental Studies/Animal Studies), Joseph LeDoux (NYU, Center for Neural Science), Björn Merker(Neuroscience), Diana Reiss (Hunter, Psychology), Peter Singer (Princeton, Philosophy), Michael Tye (Texas, Philosophy)
CONFERENCE SCHEDULE AND LOCATION:
The conference will be held at the NYU Cantor Film Center (36 E 8th St), Room 200 (the main theater on the second floor). The overflow room will be Cantor 101. The conference will run from 9:00am to 6pm on both days, with registration beforehand (beginning at 8:30). The Friday sessions will include “Invertebrates and the evolution of consciousness”, “Do fish feel pain”, and “Animal consciousness and ethics”. The Saturday sessions will include “Self-consciousness in mammals”, “Animal consciousness and theories of consciousness”, and a panel discussion. A detailed schedule will be circulated closer to the conference date.
Adam Etinson is a Lecturer in Philosophy in the School of Philosophical, Anthropological, and Film Studies at the University of St Andrews. He works on a range of topics in moral and political philosophy. Much of his recent research is in the philosophy of human rights, but he also works on topics in social epistemology (such as the problem of ethnocentrism) and is interested in the historical and theoretical foundations of liberalism. He recently became the Assistant Director of CEPPA – the Centre for Ethics, Philosophy, and Public Affairs at the University of St Andrews. For more, visit here.
12:00 PM-1:30 PM
719 Broadway, Room 1221 New York, NY 10003
Lunch will be served